MedTrace Logo

Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis

NCT02271971 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2015-11-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether supplementation with oral vitamin D (cholecalciferol) improves metabolic parameters in patients with moderate to severe psoriasis.

Conditions

  • Psoriasis
  • Metabolic Syndrome
  • Vitamin D Deficiency

Interventions

DIETARY_SUPPLEMENT

Vitamin D3

A daily 5.000 IU vitamin D3 capsule during 6 weeks.

DIETARY_SUPPLEMENT

Placebo

A daily placebo capsule during 6 weeks.

Sponsors & Collaborators

  • Pontificia Universidad Catolica de Chile

    lead OTHER

Principal Investigators

  • Sergio Niklitschek, MD · School of Medicine, Pontificia Universidad Católica de Chile

  • Ninoska Porras, MD · School of Medicine, Pontificia Universidad Católica de Chile

  • Hernán Correa, MD · School of Medicine, Pontificia Universidad Católica de Chile

  • Félix Fich, MD · School of Medicine, Pontificia Universidad Católica de Chile

  • Isidora Harz, MD · School of Medicine, Pontificia Universidad Católica de Chile

  • Arturo Borzutzky, MD · School of Medicine, Pontificia Universidad Católica de Chile

  • Luis Villarroel, MD · School of Medicine, Pontificia Universidad Católica de Chile

  • William Romero, MD · School of Medicine, Pontificia Universidad Católica de Chile

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-04-30
Completion
2015-10-31

Countries

  • Chile

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02271971 on ClinicalTrials.gov